Insider Trading Activity Nektar Therapeutics (NASDAQ:NKTR) – Director Bought 35,000 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Nektar Therapeutics (NASDAQ:NKTR)

Roy A Whitfield , Director of Nektar Therapeutics (NASDAQ:NKTR) reportedly Bought 35,000 shares of the company’s stock at an average price of 17.95 for a total transaction amount of $628,250.00 SEC Form

Insider Trading History For Nektar Therapeutics (NASDAQ:NKTR)

On 9/14/2012 Dennis L Winger, Director, bought 5,000 with an average share price of $9.18 per share and the total transaction amounting to $45,900.00.View SEC Filing

On 8/5/2013 Roy Whitfield, Director, sold 12,500 with an average share price of $12.41 per share and the total transaction amounting to $155,125.00.View SEC Filing

On 11/3/2014 Gil M Labrucherie, SVP, sold 9,900 with an average share price of $13.78 per share and the total transaction amounting to $136,422.00.View SEC Filing

On 11/24/2014 Lutz Lingnau, Director, sold 15,000 with an average share price of $15.02 per share and the total transaction amounting to $225,300.00.View SEC Filing

On 11/24/2014 Howard W Robin, CEO, sold 132,800 with an average share price of $15.02 per share and the total transaction amounting to $1,994,656.00.View SEC Filing

On 11/24/2014 Gil M Labrucherie, SVP, sold 10,500 with an average share price of $15.04 per share and the total transaction amounting to $157,920.00.View SEC Filing

On 11/25/2014 Howard W Robin, CEO, sold 600,000 with an average share price of $15.25 per share and the total transaction amounting to $9,150,000.00.View SEC Filing

Analyst Ratings For Nektar Therapeutics (NASDAQ:NKTR)
These are 9 Buy Ratings .
The current consensus rating for Nektar Therapeutics (NASDAQ:NKTR) is Buy (Score: 3.00) with a consensus target price of $27.13 , a potential (48.55% upside)

Analyst Ratings History For Nektar Therapeutics (NASDAQ:NKTR)

On 1/27/2016 Janney Montgomery Scott Initiated Coverage of rating Buy with a price target of $21.00
On 9/30/2016 Brean Capital Reiterated Rating Buy with a price target of $23.00
On 3/21/2017 J P Morgan Chase & Co Set Price Target of rating Buy with a price target of $24.00
On 3/21/2017 BTIG Research Boost Price Target of rating Positive with a price target of $22.00 to $27.00
On 4/11/2017 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $29.00
On 5/10/2017 Aegis Reiterated Rating Buy with a price target of $27.00
On 7/18/2017 William Blair Reiterated Rating Outperform

Recent Trading Activity for Nektar Therapeutics (NASDAQ:NKTR)
Shares of Nektar Therapeutics closed the previous trading session at 18.82 up +0.56 3.07% with 1,240,270 shares trading hands.